Get Started
Companies › MRUS

Merus

MRUS · NASDAQ
Commercial StageMixed

Merus developed a differentiated Biclonics® platform generating bispecific antibodies with best-in-class clinical profiles in head & neck cancer (petosemtamab) and NRG1 fusion cancers (zenocutuzumab/BIZENGRI). The platform's ability to produce novel bispecifics targeting hard-to-drug tumor antigens made Merus a strategic acquisition target for antibody-focused acquirers seeking late-stage oncology assets.

Market Cap
$8.0B
Cash Runway
—
Pipeline
2 Assets
Priority
Low
Investment Thesis

Bull Case

  • Petosemtamab 63% ORR in 1L HNSCC combination — substantially above historical standard of care with pembrolizumab alone
  • Dual BTDs signal strong FDA engagement and potential accelerated pathway to approval
  • BIZENGRI approval establishes regulatory credibility and commercial infrastructure
  • Two Phase 3 trials running simultaneously in HNSCC — multiple shots on goal for registration
  • Biclonics platform enables multiple follow-on programs beyond lead assets

Bear Case

  • Phase 2 data in combination — need Phase 3 confirmation of ORR and PFS benefit
  • HNSCC market competitive with multiple I-O combinations in development
  • BIZENGRI targets ultra-rare NRG1 fusions (1-2% of NSCLC) — limited commercial opportunity as standalone
  • Bispecific manufacturing complexity could limit scale-up

Pipeline

Asset Target Stage Lead Indication Next Catalyst
Petosemtamab (MCLA-158) EGFR x LGR5 Phase 3 Head and Neck Squamous Cell Carcinoma (HNSCC) Phase 3 interim readout (1L or 2L/3L HNSCC) (2026)
Zenocutuzumab (BIZENGRI®) HER2 x HER3 (NRG1 fusions) Approved NRG1 fusion-positive NSCLC and pancreatic adenocarcinoma (2L+) Confirmatory trial data (TBD)
Data sourced exclusively from public filings, corporate presentations, and published clinical data. For informational purposes only. Not investment advice. Satya Bio does not provide recommendations to buy or sell securities. Terms · Privacy